Biosimilars: US prescriber’s attitudes and perceptions revealed

Biosimilars/Research | Posted 28/07/2023 post-comment0 Post your comment

report based on the 2021 survey carried out by the Alliance for Safe Biologic Medicines (ASBM) reveals the views of prescribing physicians, regarding the prescribing, substitution and interchangeability of biosimilars [1].

Clinician1 MD002408 V13C22

In the US, a legal framework for approving biosimilars was established via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). At the time of writing of this report, 37 biosimilars have been approved. Some biosimilars in the US can be designated as ‘interchangeable’, which means they can be automatically substituted at the pharmacy level.

In September 2021, the ASBM conducted a web-based quantitative survey with 401 participants practicing medicine in the US. Prescribers were asked for their views on substitution of, as well as their familiarity with, knowledge of, attitudes to, and beliefs in, biosimilars.

Overall, the survey revealed that most physicians are comfortable prescribing biosimilars and comfortable switching stable patients to biosimilar product. Over half of physicians are more likely to prescribe biosimilars with interchangeable status and they are comfortable with pharmacy-level substitution of these products. However, the majority want to keep the authority to prevent pharmacy-level substitution if they specify so. When it came to switching patients to a biosimilar for non-medical reasons, the majority were comfortable doing this but fewer than half were comfortable with third-party switching. In addition, most physicians favoured a scenario where multiple products, including innovator and biosimilars are reimbursed, and biosimilars may be encouraged for new patients with no automatic substitution permitted. 

In general, physicians in the US are confident when it comes to prescribing biosimilars. The survey also sheds light on how they feel about the interchangeable designation, indicating a confidence in them. It also reveals how they feel about biological drugs switching choices made by them, pharmacists and payers. 

Related articles
The successful uptake of biosimilars in Europe and the US

Survey demonstrates US pharmacist biosimilar knowledge gaps

Biosimilar adoption and prescribing in Japan: a physician opinion survey

US prescribers’ views on the naming and labelling of biologicals

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Actualización de la declaración de posición de GADECCU sobre los biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Actualización de la declaración de posición de GADECCU sobre los biosimilares

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

Reference
1. McKibbin RD, Reilly MS. US prescribers' attitudes and perceptions about biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2022;11(3):96-103. doi:10.5639/gabij.2022.1103.016

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.

 

comment icon Comments (0)
Post your comment
Related content
Four steps for streamlining biosimilars development
ST002293
Biosimilars/Research Posted 03/08/2023
Clinical trial advances for Kashiv and Celltrion
Clinical Trials 2 V13K29
Biosimilars/Research Posted 24/07/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010